Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Recurrence 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 25Lenalidomide 20Cyclophosphamide 18obinutuzumab 8Vincristine 8Doxorubicin 8Prednisone 7Bendamustine Hydrochloride 7tazemetostat 6ibrutinib 6Biopsy 6venetoclax 5pembrolizumab 5fludarabine 5Specimen Handling 5CT-P10 5fludarabine phosphate 4R-CHOP protocol 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Prednisolone 3Etoposide 3tocilizumab 2copanlisib 2axicabtagene ciloleucel 2atezolizumab 2acalabrutinib 2abexinostat 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Follicular × tafasitamab × Clear all
NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡